Omega-3 Supplements and Heart Disease: A Practical Guide for GPs
Aug 27, 2025
Updated · PassGP
Clinical reasoning · CCE practice
The right evidence for the right patient.
“Should I keep taking fish oil?” sounds straightforward. In practice, the answer depends on the product, the reason it was started and the outcome the patient hopes to achieve. A discussion about dietary fish is different from a decision about an over-the-counter supplement or prescription icosapent ethyl.
For GPs, the useful question is: what evidence supports this formulation for this patient? Lowering a triglyceride result and preventing cardiovascular events are separate outcomes.
Start by identifying the product
Product | Clinical interpretation |
Fish and other dietary sources | Support a heart-healthy eating pattern. The Heart Foundation recommends two to three serves of fish each week, including oily fish. Dietary advice does not establish an indication for capsules. [1] |
Ordinary over-the-counter fish oil | Usually contains EPA and DHA in varying amounts. The AHA/ACC chronic coronary disease guideline does not recommend nonprescription omega-3 supplements for reducing cardiovascular events. [2] |
Prescription icosapent ethyl | A specific EPA-based medicine with evidence and an Australian indication for selected statin-treated patients. It is not interchangeable with retail fish oil. [3] [4] |
Why the cardiovascular evidence needs precision
REDUCE-IT found fewer cardiovascular events with prescription icosapent ethyl in selected high-risk, statin-treated patients with elevated triglycerides. STRENGTH, which tested a different high-dose prescription EPA/DHA formulation, did not demonstrate a significant cardiovascular-event reduction. STRENGTH was not a trial of ordinary retail capsules. Together, these findings show why the evidence must be interpreted by formulation and population rather than attributed to all “omega-3”. [4] [5]
In Australia, the TGA indication for icosapent ethyl covers adults taking a statin who have high cardiovascular risk, triglycerides at least 1.7 mmol/L, and either established cardiovascular disease or diabetes with at least one additional cardiovascular risk factor. Meeting these broad criteria prompts an individual treatment assessment; it does not establish that every patient should receive it or qualifies for subsidy. [3]
Safety belongs in that assessment. Australian product information identifies atrial fibrillation/flutter and bleeding risks with icosapent ethyl, with particular attention to concurrent antiplatelet or anticoagulant treatment. Review the patient's history, dose and co-prescribed medicines when discussing these risks. [6]
A CCE-style worked example
PassGP teaching example: A patient takes six daily supplements, including fish oil, glucosamine and turmeric. He has stable ischaemic heart disease and asks whether he should continue fish oil.
The clinical starting point: established ischaemic heart disease makes this a secondary-prevention discussion. An explanation based only on primary-prevention evidence does not answer his question. The stem does not tell you his triglycerides, prescription medicines or exact supplement, so those details must be clarified.
A focused candidate approach
The following is PassGP's teaching application of the evidence, rather than an official RACGP marking guide:
- Understand his purpose. Ask what he hopes the supplement will achieve, who recommended it and whether he has concerns about stopping.
- Identify the preparation. Check the label, EPA/DHA content, daily dose and whether it is prescribed. Review all medicines and supplements together.
- Establish the clinical context. Review recent lipids, statin treatment and adherence, any separate documented indication, and AF or bleeding history.
- Make a proportionate recommendation. If ordinary fish oil is self-prescribed solely for coronary protection, discuss stopping after checking for another indication. Elevated triglycerides warrant assessment; they do not automatically justify continuing that product. [2] [3]
- Agree the wider plan. Address cost and pill burden, reinforce established secondary-prevention treatment and lifestyle measures, and arrange follow-up for unresolved findings. [2]
How the conversation might sound
“You're trying to protect your heart, and I understand why you started it. Because you already have coronary disease, we need treatments that reduce your chance of another heart problem. Ordinary fish oil capsules have not shown a reliable extra benefit for that purpose. A different prescription medicine can help some people with raised triglycerides, but it isn't interchangeable with shop-bought fish oil. Let's check your product, medicines and blood results, then decide together whether this supplement still has a useful role.”
Key takeaways
- Stable IHD requires secondary-prevention reasoning.
- Identify the formulation before discussing benefit or stopping treatment.
- Triglyceride lowering alone does not establish cardiovascular-event reduction.
- Good exam performance connects evidence, patient priorities and a specific plan.
Sources
- Heart Foundation. Omega fats and heart health.
- AHA/ACC. 2023 chronic coronary disease guideline: key recommendations.
- TGA. Vazkepa: approved therapeutic indication.
- Bhatt et al. REDUCE-IT. New England Journal of Medicine, 2019.
- Nicholls et al. STRENGTH. JAMA, 2020.
- Australian Commission on Safety and Quality in Health Care. Vazkepa product information.
You know the medicine.
We teach you the exam.
Build a consistent approach to clinical reasoning with PassGP practice and teaching.
